key: cord-0951200-ibh4em3d
authors: Caramello, Valeria; Boccuzzi, Adriana; Basile, Vittoria; Ferraro, Anita; Macciotta, Alessandra; Catalano, Alberto; Costa, Giuseppe; Vineis, Paolo; Sacerdote, Carlotta; Ricceri, Fulvio
title: Are antigenic tests useful for detecting SARS-CoV-2 infections in patients accessing to emergency departments? Results from a North-West Italy Hospital
date: 2021-05-21
journal: J Infect
DOI: 10.1016/j.jinf.2021.05.012
sha: 171fa37f0d8724ab2c48f740a9c33241d56133c2
doc_id: 951200
cord_uid: ibh4em3d

nan

In the article "Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: A preliminary report." [1] , Turcato et al presented a study on the use of rapid antigenic tests (Ag-RDTs) instead of the usual real time reverse transcription polymerase chain reaction (RT-PCR) assay to detect the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the context of Emergency Departments (ED). They observed a general good sensitivity and specificity, lower in the subgroup of asymptomatic patients. Their conclusion is in favour of the use of Ag-RDTs in EDs as an additional tool to address the challenge of containing the SARS-CoV-2 pandemic.

We agree with the authors that the development of reliable but cheaper and faster point-of-care diagnostic tests was expected to be useful either for population-screening or as first aid tests in the emergency room [2, 3] . Data on the sensitivity and specificity of currently available Ag-RDTs derive from studies that vary in design, setting, population and type of specimen, thus strongly limiting the comparability and ability to make general inferences. Sensitivity appears to be highly variable, ranging from 29 to 94% compared to the RT-PCR test, but specificity is consistently high (>97%) [4] [5] [6] [7] . Ag-RDTs were found to perform better in patients with high viral loads (Ct values ≤25 or >106 genomic virus copies/mL) [5, 7, 8, 15, 16, 18, 19] which usually happens in the presymptomatic (0.5-3 days before symptom onset) and early symptomatic phases of the illness (within the first week from symptom onset) but limited data are available about other possible individual modifiers of the accuracy of the assay. A recent Cochrane review highlighted that patients' characteristics were not available or poorly detailed in many studies, with only three out of 22 studies coming from an ED setting [8] .

Between October 26 th and November 10 th 2020, 455 patients accessed the ED of San Luigi Gonzaga University Hospital in Orbassano (Turin, Italy) and 324 underwent both RT-PCR and Ag-RDT testing. This period corresponds to the first two weeks of the second pandemic wave, with a weekly incidence of SARS-CoV-2 infection in the Region of about 500 confirmed cases/100000

inhabitants. Data were obtained as part of an observational study described elsewhere [9] and a detailed presentation of methods is available in supplementary material.

The prevalence of SARS-CoV-2 infection in this cohort was 65% measured using RT-PCR as a gold standard. Supplementary Table 1 Table 3 ). On the contrary, false negative patients were significantly younger and they were tested significantly later after symptoms onset compared with true negative patients (Table 1) . Moreover, fever (64.3% vs 19.6%, p<0.0001) and cough (42.9% vs 15.0%, p=0.0003) were significantly more frequent in false than true negatives, while chronic obstructive pulmonary disease was more frequent in true than false negatives, with a borderline significance (16.5% vs 4.8%, p=0.06). Few true negative patients had bilateral pneumonia (n= 10, 9.4%), that was highly present in false negative patients (n=25, 61.0%, p-value for difference < 0.0001) and multivariable analysis confirm these results, suggesting that wrong group allocation for negative patients occurred more frequently in patients with fever, cough, and pneumonia, while it was less likely in patients with COPD.

The infection prevalence and the clinical context where the test is used affect the effectiveness of the test itself [10] : the ideal test in a crowded ED context should help in identifying asymptomatic patients arriving to the ED for reasons other than COVID-19, who are concurrently found COVID-19 positive.

Our results suggest that a negative Ag-RDT test should not exclude COVID-19 in patients that clinically have symptoms that are strongly suggestive of COVID-19. Ag-RDTs alone had a low negative predictive value (we cannot trust a negative result of the test), thus they need to be evaluated in association with clinical judgement. A high level of suspicion should be maintained in patients with fever, cough or pneumonia notwithstanding a negative Ag-RDT. Since the predictive value is strictly related to the prevalence of disease, and then to the pre-test odds, Ag-RDTs are not really useful in settings where the prevalence of disease is high or in patients with high pre-test odds. On the contrary, in periods with low prevalence of the disease or in patients with a low pretest odds (asymptomatic) or with symptoms probably related to a known COPD, Ag-RDTs can be used alone and we can trust a negative result.

In conclusion, our results confirm the limits of antigenic tests as first line screening tests in settings with high prevalence of disease or in patients with high pre-test odds, where a negative test is not informative (i.e. in ED in a pandemic period). This suggests that in these situations the antigenic test should be integrated in a clinical algorithm. 

Clinical application of a rapid antigen test for the detection of SARS-CoV-2 infection in symptomatic and asymptomatic patients evaluated in the emergency department: A preliminary report

Urgent need of rapid tests for SARS CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2

Recommendations for use of antigenic tests in the diagnosis of acute SARS-CoV-2 infection in the second pandemic wave: attitude in different clinical settings

Evaluation of rapid antigen test for detection of SARS-CoV-2 virus

SARS-CoV-2 qRT-PCR Ct value distribution in Japan and possible utility of rapid antigen testing kit

Head-to-head comparison of four antigenbased rapid detection tests for the diagnosis of SARS-CoV-2 in respiratory samples

Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis

Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev

Clinical characteristics and management of COVID-19 patients accessing the emergency department in a hospital in Northern Italy in March and

Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms

Authors would like to thank Marco Alvich, Rebecca Tasca, Sara Roetti, and Selene Demaria for their help in collecting data.

The authors received no specific funding for this work.

All authors declare no conflict of interests Positive and negative predictive value estimates in relation to prevalence, using the sensitivity and specificity of the test found in our population (sensitivity = 0.800; specificity = 0.939).